|
NEW YORK (Reuters Health) - Ziprasidone, sold under the
trade name Geodon, is well tolerated by patients and shows
long-term efficacy as maintenance therapy for patients with
schizophrenia who have not responded to other drugs, according
to the results of a clinical trial published in the Journal
of Clinical Psychiatry.
Dr. Antony D. Loebel, of Pfizer Inc. in New York, and colleagues
studied patients with a diagnosis of treatment-resistant
schizophrenia based on DMS-III-R criteria who were treated
for 1 year with ziprasidone, a second-generation atypical
antipsychotic.
Sixty-two patients had participated in an earlier 12-week
study in which 32 patients received ziprasidone and 30 received
chlorpromazine.
Of the 41 patients (73 percent) who responded to ziprasidone
or chlorpromazine, 30 were able to maintain this response
on ziprasidone.
"Over 1 year of continuous treatment, ziprasidone
was well tolerated, with a relatively low rate of discontinuation,
and was associated with favorable effects on weight and
metabolic parameters," the researchers report. There
were no changes in movement disorder measures.
Further studies are warranted to confirm these preliminary
findings, Loebel and colleagues conclude.
SOURCE: Journal of Clinical Psychiatry, September 2007.
hoodia weight loss learn the facts about hoodia gordonii.
Pharmacy Online- offering online prescription medication.
Online pharmacy - ziprasidone.
Cheap web pharmacy FDA approved!
Mexican pharmacies - no prescription online order of mexican drugs.
|
